Medinos data shows these complaints are common enough that simple, repeatable measures usually resolve them without stopping therapy
In the OASIS 1 trial, subjects receiving oral semaglutide (50 mg) lost 17.4% of their body weight at 68 weeks , while the placebo group achieved only 1.8% weight loss
Phase 2 trial data Tirzepatide Phase 3 trials (SURPASS and SURMOUNT programs) demonstrated weight loss of 15 to 22.5% body weight depending on dose and study population
Have you considered using available tools like online calculators, mobile apps, and dosing charts
Your provider will evaluate your health history, BMI, and weight-related conditions to determine if youre a candidate for semaglutide and outline a plan to help you succeed
GLP-1 and dual-agonist breakthroughs in metabolic disease